SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology
+$0.31 today
- Market cap
- $3.66B
- Beta
- 2.53
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.17
Volume 35.53M
Average 7.79M
SLS EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
SELLAS Life Sciences Group, Inc.NASDAQ: SLS
EPS (Diluted) · Q3 FY2026 · quarter ended Sep 2026
EPS (Diluted) remains negative
Q3 FY2026 EPS (Diluted) was -$0.05, compared with -$0.06 a year earlier. Trailing-twelve-month EPS (Diluted) was -$0.2.
Context
- EPS (Diluted) grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 1 analysts of -$0.21 (+18.0%) for the fiscal year ending Dec 2026, a slowdown from the +50.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$0.05+0.0% QoQ
- Last fiscal yearDec 2025
- -$0.25+50.0% YoY
- LTMSep 2026
- -$0.2+31.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +20.1% | +0.0% | -20.1 pp |
| 1 year | +50.0% | +18.0% | -32.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (0.25) USD
- Year-over-year change
- +50.0%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.25) | +50.0% |
| FY2024 | 2024-12-31 | (0.50) | +62.7% |
| FY2023 | 2023-12-31 | (1.34) | +37.1% |
| FY2022 | 2022-12-31 | (2.13) | -59.0% |
| FY2021 | 2021-12-31 | (1.34) | — |
EPS (Diluted) vs competitors
How SLS compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +31.5% is the 5th highest of 11, against a peer median of +14.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $7.85 USD | +78.4% | +61.6% | |
| LTM Aug 2026 | $2.31 USD | +177.8% | — | |
| LTM Sep 2026 | -$0.2 USD | +31.5% | — | |
| LTM Mar 2026 | -$1.06 USD | +37.3% | — | |
| LTM Mar 2026 | -$1.1 USD | -23.6% | — | |
| LTM Mar 2026 | -$1.19 USD | +19.0% | — | |
| LTM Mar 2026 | -$1.6 USD | +55.4% | — | |
| LTM Sep 2026 | -$2.65 USD | +10.2% | — | |
| LTM Mar 2026 | -$3.53 USD | +6.4% | — | |
| LTM Mar 2026 | -$10.91 USD | -442.8% | — | |
AAPGAscentage Pharma Group International | FY2025 | -CN¥13.56 CNY | -153.0% | — |
| Peer median (excluding SLS) | — | +14.6% | +61.6% | |
Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.6M | 1M | 0 | 0 | 0 |
| Cost of Revenue | 200K | 100K | 0 | 0 | 0 |
| Gross Profit | 7.4M | 900K | 0 | 0 | 0 |
| Gross Margin | 97.4% | 90.0% | — | — | — |
| Research & Development | 21.37M | 30.27M | 24.01M | 19.1M | 16.02M |
| Selling, General & Admin | 11.32M | 12.58M | 13.86M | 12.42M | 12.25M |
| Operating Expenses | 32.69M | 42.85M | 37.87M | 31.51M | 28.27M |
| Depreciation & Amortization | 1.27M | 457K | 37.87M | 31.51M | 0 |
| EBITDA | (18.32M) | (31.49M) | 529K | 632K | (26.86M) |
| EBITDA Margin | -241.1% | -3149.3% | — | — | — |
| Operating Income | (25.29M) | (41.95M) | (37.87M) | (31.51M) | (28.27M) |
| Operating Margin | -332.8% | -4195.0% | — | — | — |
| Interest Income | 6K | 317K | 525K | 632K | 1.41M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.36M | 649K | 529K | 632K | 1.41M |
| Income Before Tax | (20.94M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Pre-Tax Margin | -275.5% | -4130.1% | — | — | — |
| Income Tax Expense | (237K) | 0 | 0 | 0 | 0 |
| Net Income | (20.7M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Net Margin | -272.4% | -4130.1% | — | — | — |
| EPS (Basic) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| EPS (Diluted) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| Weighted Avg Shares | 15.48M | 19.4M | 27.78M | 61.2M | 109.05M |
| Weighted Avg Shares (Diluted) | 15.48M | 19.4M | 27.78M | 61.2M | 109.05M |
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
Intrinsic Alpha fair value
Locked
Current Price
$17.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.